Business description: GlaxoSmithKline plc

GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows:

- pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%);

- OTC and parapharmaceutical medicine (30.7%);

- vaccines (28%).

Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).

Sales by Activity: GlaxoSmithKline plc

Fiscal Period: December 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP) 2025 (GBP)

Commercial Operations

- 2.93TCr 3.03TCr 3.14TCr 3.27TCr

Vaccines

677.8Cr - - - -

Pharmaceuticals

1.77TCr - - - -

Consumer Healthcare

960.7Cr - - - -

Geographical breakdown of sales: GlaxoSmithKline plc

Fiscal Period: December 2021 (GBP) 2022 (GBP) 2023 (GBP) 2024 (GBP) 2025 (GBP)

United States (US)

1.51TCr 1.45TCr 1.58TCr 1.64TCr 1.69TCr

International

1.8TCr 1.41TCr 1.38TCr 1.43TCr 827.5Cr

Europe

- - - - 685Cr

United Kingdom (UK)

98Cr 70Cr 69Cr 71Cr 68Cr

Executive Committee: GlaxoSmithKline plc

Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Chief Tech/Sci/R&D Officer - 19/01/2022
Chief Tech/Sci/R&D Officer - 01/12/2021

Composition of the Board of Directors: GlaxoSmithKline plc

Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Director/Board Member 66 01/05/2020
Director/Board Member 64 06/05/2021
Director/Board Member 68 01/01/2022
Director/Board Member 59 18/07/2022
Director/Board Member 69 01/09/2022
Director/Board Member 64 01/05/2023
Director/Board Member 61 01/10/2023

Shareholders: GlaxoSmithKline plc

NameStocks%Valuation
Fidelity Management & Research Co. LLC
5.741 %
23,22,29,061 5.741 % 5 771 M p
Vanguard Capital Management LLC
2.906 %
11,75,45,072 2.906 % 2 921 M p
BlackRock Investment Management (UK) Ltd.
2.204 %
8,91,58,335 2.204 % 2 216 M p
Dodge & Cox
2.195 %
8,88,16,040 2.195 % 2 207 M p
BlackRock Advisors (UK) Ltd.
1.729 %
6,99,31,678 1.729 % 1 738 M p
NameStocks%Valuation
Fidelity Management & Research Co. LLC
3.21 %
6,49,20,766 3.21 % 3 214 M p
Dodge & Cox
2.135 %
4,31,83,117 2.135 % 2 138 M p
Fisher Asset Management LLC
1.748 %
3,53,51,693 1.748 % 1 750 M p
PRIMECAP Management Co.
1.245 %
2,51,92,138 1.245 % 1 247 M p
RBC Private Counsel (USA), Inc.
0.4779 %
96,67,048 0.4779 % 479 M p

Holdings: GlaxoSmithKline plc

NameStocks%Valuation
12,70,54,52475% 3 323 M $
26,30,29,79482.59% 304 M $
26,08,4192.7% 134 M $
85,50,9545.05% 97 M $
1,82,45,6919.25% 66 M $
6,68,5260.28% 59 M $
13,33,3331.52% 43 M $
4,34,6426.46% 28 M $
3,40,4340.24% 21 M $
7,73,2787.95% 20 M $

Company details: GlaxoSmithKline plc

GSK Plc

79 New Oxford Street

WC1A 1DG, London

+44 20 8047 5000

http://www.gsk.com
address GlaxoSmithKline plc

Group companies: GlaxoSmithKline plc

NameCategory and Sector
Regional Banks
Pharmaceuticals: Major
Biotechnology
Financial Conglomerates
Pharmaceuticals: Major

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average +0.33%-4.76%+25.01%+75.64% 45TCr
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline plc
  1. Stock Market
  2. Stocks
  3. GSK Stock
  4. Stock
  5. Company GlaxoSmithKline plc